Latest Pharmaceutical Royalties News

Page 1 of 1

Neuren Confirms DAYBUE Sales Projection Could Boost Royalties to $700m by 2028

Neuren Pharmaceuticals has affirmed the material impact of Acadia’s projection that DAYBUE global net sales could reach approximately US$700 million by 2028, underpinning its royalty revenue outlook.

Ada Torres

19 Jan 2026

Top